The humoral response to Gardasil® over four years as defined by Total IgG and competitive luminex immunoassay

Human Vaccines

Volumn 7, Issue 2, 2011, Pages 230-238

  Brown, Darron R ^a   Garland, Suzanne ^b,c   Ferris, Daron G ^d   Joura, Elmar ^e   Steben, Marc ^f   James, Margaret ^g   Radley, David ^g   Vuocolo, Scott ^g   Garner, Elizabeth I O ^g   Haupt, Richard M ^g   Bryan, Janine T ^g  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROYAL WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antibodies; HPV; Vaccine

Indexed keywords

EPITOPE; WART VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; COMPETITIVE LUMINEX IMMUNOASSAY; CONTROLLED STUDY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOASSAY; NONHUMAN; PAPILLOMAVIRUS INFECTION; SEROCONVERSION; SERUM; TOTAL IGG LUMINEX IMMUNOASSAY; VACCINATION;

ANTIBODIES, VIRAL; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; PAPILLOMAVIRUS VACCINES; TIME FACTORS; VIRION;

EID: 79952468781     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.2.13948     Document Type: Article

References (56)

1. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila Pa) 2009; 2:868-78.
2. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369:1861-8. (Pubitemid 46829356)
3. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43.
4. II F. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27.
5. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369:1693-702.
6. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70. (Pubitemid 46977438)
7. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-55.
8. Orozco JJ, Carter JJ, Koutsky LA, Galloway DA. Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. J Virol 2005; 79:9503-14. (Pubitemid 41022294)
9. Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 2007; 25:4324-33. (Pubitemid 46635934)
10. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 2006; 24:106-13.
11. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008; 109:15-21.
12. Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine 2008; 26:62-7.
13. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci 1995; 92:11553-7. (Pubitemid 26014152)
14. Christensen ND, Dillner J, Eklund C, Carter JJ, Reed CA, Cladel NM, et al. Surface conformational and linear epitopes on HPV16 and HPV18 virus-like particles as defined by monoclonal antibodies. Virology 1996; 223:174-84. (Pubitemid 26302057)
15. Carter JJ, Wipf GC, Madeleine MM, Schwartz SM, Koutsky LA, Galloway DA. Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol 2006; 80:4664-72.
16. Lin YL, Borenstein LA, Selvakumar R, Wettstein FO. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 1992; 187:612-9.
17. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69:3959-63.
18. Jansen KU, Rosolowsky M, Schultz LD, Markus HZ, Cook JC, Donnelly JJ, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995; 13:1509-14.
19. Ghim SJ, Young R, Jenson AB. Antigenicity of bovine papillomavirus type 1 (BPV-1) L1 virus-like particles compared with that of intact BPV-1 virions. J Gen Virol 1996; 77:183-8. (Pubitemid 26044136)
20. Kirnbauer R, Chandrachud LM, O'Neill BW, Wagner ER, Grindlay GJ, Armstrong A, et al. Virus-like particle of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996; 219:37-44. (Pubitemid 26180381)
21. Lowe RS, Brown DR, Bryan JT, Cook JC, George HA, Hofmann KJ, et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 1997; 176:1141-5. (Pubitemid 27460976)
22. Christensen ND, Höpfl R, DiAngelo SL, Cladel NM, Patrick SD, Welsh PA, et al. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 1994; 75:2271-6. (Pubitemid 24282240)
23. Rose RC, Reichman RC, Bonnez W. Human papillomavirus type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 1994; 75:2075-9. (Pubitemid 24243091)
24. Brown DR, Bryan JT, Schroeder JM, Robinson TS, Fife KH, Wheeler CM, et al. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radio-immunoassay titer. J Infect Dis 2001; 184:1183-6. (Pubitemid 33010472)
25. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-51. (Pubitemid 35340782)
26. Ault KA, Giuliano AR, Edwards RP, Tamms G, Kim LL, Smith JF, et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 2004; 22:3004-7. (Pubitemid 39037200)
27. Yeager MD, Aste-Amezaga M, Brown DR, Martin MM, Shah MJ, Cook JC, et al. Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies. Virology 2000; 278:570-7. (Pubitemid 32012790)
28. Christensen ND, Cladel NM, Reed CA, Budgeon LR, Embers ME, Skulsky DM, et al. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 2001; 291:324-34. (Pubitemid 34095188)
29. Culp TD, Spatz CM, Reed CA, Christensen ND. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology 2007; 361:435-46.
30. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8.
31. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1459-66. (Pubitemid 44863348)
32. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial. Obstet Gynecol 2006; 107:18-27.
33. Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26:6844-51.
34. Munoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373:1949-57.
35. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by a multiplexed luminex assay. Clin Diagnostic Lab Immunol 2003; 10:108-15.
36. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16 and 18. Clin Diagn Lab Immunol 2005; 12:959-69.
37. Opalka D, Matys K, Bojczuk P, Green T, Gesser R, Saah A, et al. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol 17:818-27.
38. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16 and 18. Vaccine 2006; 24:5571-83.
39. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25:4931-9. (Pubitemid 46843434)
40. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 1996; 224:477-86. (Pubitemid 26364495)
41. Ryding J, Dahlberg L, Wallen-Ohman M, Dillner J. Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. J Gen Virol 2007; 88:792-802. (Pubitemid 46359548)
42. Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009; 200:166-71.
43. Rowhani-Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009; 27:5612-9.
44. Wang X, Wang Z, Christensen ND, Dillner J. Mapping of human serum-reactive epitopes in virus-like particles of human papillomavirus types 16 and 11. Virology 2003; 311:213-21. (Pubitemid 36794224)
45. Wang ZH, Christensen N, Schiller JT, Dillner J. A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol 1997; 78:2209-15. (Pubitemid 27387034)
46. Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996; 223:174-84. (Pubitemid 26302057)
47. Smith JF, Kowalski R, Esser MT, Brown MJ, Bryan JT. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11. Hum Vaccin 2008; 4:134-42. (Pubitemid 351881182)
48. Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007; 3:109-15. (Pubitemid 47501028)
49. Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, Schiller JT. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol 2007; 81:8784-92. (Pubitemid 47242851)
50. Roberts CC, Tadesse AS, Sands J, Halvorsen T, Schofield TL, Dalen A, et al. Detection of HPV in Norwegian cervical biopsy specimens with type-specific PCR and reverse line blot assays. J Clin Virol 2006; 36:277-82. (Pubitemid 44088487)
51. Hamilton RG. Engineered human antibodies as immunologic quality control reagents. Ann Biol Clin (Paris) 1990; 48:473-7. (Pubitemid 20356873)
52. Christensen ND, Kreider JW, Cladel NM, Galloway DA. Immunological cross-reactivity to laboratory-produced HPV 11 virions of polysera raised against bacterially derived fusion proteins and synthetic peptides of HPV-6b and HPV-16 capsid proteins. Virology 1990; 175:1-9. (Pubitemid 20093055)
53. Christensen ND, Kreider JW, Cladel NM, Patrick SD, Welsh PA. Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J Virol 1990; 64:5678-81. (Pubitemid 20364570)
54. Christensen ND, Kreider JW, Shah KV, Rando RF. Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J Gen Virol 1992; 73:1261-7.
55. Christensen ND, Kreider JW. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol 1990; 64:3151-6. (Pubitemid 20219515)
56. Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, et al. Immunological analyses of human papillomavirus capsids. Vaccine 2001; 19:1783-93. (Pubitemid 32175741)